ERAS Erasca, Inc.
$15.88▼ -0.94%
Healthcare
Other
After hours
$16.52▲ +4.00%
Sep 11, 7:30 PM ET
Volume 2.88M
Avg Volume (10D) 4.60M
Key Metrics & Fundamentals
Market Cap
$5.55B
P/E Ratio
–
Div Yield
–%
52W Range
1.53 - 24.28
% vs 50 MA
-12.57%
% vs 200 MA
21.18%
RSI-14
37.8
MACD Histogram
-0.2200
Beta (1Y vs SPY)
1.16
Free Cash Flow
-$27.28M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$46.90M
COGS
–
Operating Exp
$47.62M
Operating Income
-$47.62M
EBIT
-$47.62M
Pretax Income
-$44.08M
Net Income
-$44.08M
EPS (Diluted)
-0.14
Price & Volume History
Loading chart…
Recent News
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
GlobeNewswire · Sep 10, 2026 12:00 PM
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire · Sep 8, 2026 11:00 AM
FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage
Insider Monkey · Sep 4, 2026 6:40 PM
Erasca's ERAS-0015 Gets FDA Fast Track Designation for Metastatic Pancreatic Cancer
MT Newswires · Aug 24, 2026 12:45 PM
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
GlobeNewswire · Aug 24, 2026 12:00 PM
BofA Adjusts Price Target on Erasca to $20 From $18
MT Newswires · Aug 14, 2026 11:46 AM
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
GlobeNewswire · Aug 12, 2026 12:30 PM
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
GlobeNewswire · Aug 11, 2026 8:01 PM
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Aug 10, 2026 8:01 PM
Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns
Simply Wall St. · Jul 16, 2026 3:24 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ERAS's money flow as a full page
Social Sentiment
Avg -0.63 · 3 posts
StubHub stock tanks 20% as CEO says it is not giving guidance for current quarter
r/stocks · Nov 13, 2025
The post expresses strong negative sentiment due to losses, dilution, and criticisms of the company's business model and leadership, reflecting significant investor concerns.
negative
-0.70
Goldman Sachs Chief, Predicting A Major Wave Of AI-Driven Productivity
r/stocks · Nov 13, 2025
The comments express significant skepticism about AI’s impact, suggest potential layoffs for tech companies (including those investing in AI), and warn of a possible ‘scam,’ indicating a bearish outlook on ERAS.
negative
-0.60
NewsDiscussionBank of America says growth stocks are in a bubble exceeding the 'dot-com' and 'nifty fifty' eras.
r/wallstreetbets · Feb 17, 2025
The post expresses a bearish sentiment towards growth stocks, driven by a potential market bubble and a 40% S&P 500 decline, suggesting a negative outlook for ERAS.
negative
-0.60
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.